Table 1.
Baseline patient and disease characteristics by allocated surgery
| All randomized participants | Open surgery (n = 266) | Hybrid surgery (n = 267) |
|---|---|---|
| Sex | ||
| Male | 227 | 225 |
| Female | 39 | 42 |
| Age (years), mean (s.d.) | 66 (9) | 67 (9) |
| BMI (kg/m2), mean (s.d.) | 27 (4) | 27 (4) |
| POSSUM physiological score, mean (s.d.), n* | 18 (4) n = 187 | 18 (4) n = 189 |
| Number WHO performance status score 1+, (%)* | 65/200 (32) | 64/196 (32) |
| Neoadjuvant treatment; n (%) | ||
| Chemotherapy | 176 (66) | 170 (64) |
| Chemoradiotherapy | 45 (17) | 49 (18) |
| None | 45 (17) | 48 (18) |
| Tumour histologic findings; n (%)† | ||
| Adenocarcinoma | 237 (90) | 235 (89) |
| Squamous cell carcinoma | 25 (9) | 26 (10) |
| Adenosquamous | 2 (1) | 2 (1) |
| High-grade dysplasia (internal pilot) | 1 | 3 (1) |
| Location of tumour in oesophagus; n (%)‡ | ||
| Upper third | 1 | 0 |
| Middle third | 8 (7) | 25 (10) |
| Lower third/Siewert I | 198 (75) | 201 (77) |
| Junctional tumour, Siewert II | 40 (15) | 29 (11) |
| Junctional tumour, Siewert III | 8 (3) | 7 (3) |
| Pretreatment clinical tumour category; n (%)†,‡ | ||
| cT1 | 23 (9) | 20 (8) |
| cT2 | 55 (21) | 58 (22) |
| cT3 | 179 (67) | 175 (66) |
| cT4a | 8 (3) | 11 (4) |
| Pretreatment clinical nodal category; n (%) | ||
| cN0 | 128 (48) | 109 (40) |
| cN1 | 98 (37) | 119 (45) |
| cN2/cN3 | 40 (15) | 39 (15) |
*Not collected for pilot-phase participants at Plymouth. †Not recorded for one patient in each group as patient withdrew from routine data follow-up before collection. ‡Not recorded for two patients allocated to hybrid surgery due to withdrawal from routine data follow-up before collection.